TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

METAPROTERENOL SULFATE

METAPROTERENOL SULFATE
Approved 1987-08-17
Jump to: Indications Approvals Trials Competitors Safety Patents
15
Indications
--
Phase 3 Trials
38
Years on Market

Details

Status
Discontinued
First Approved
1987-08-17
Routes
INHALATION, ORAL
Dosage Forms
SOLUTION, TABLET, SYRUP

Companies

NEPHRON HERITAGE PHARMA WATSON LABS DEY AstraZeneca STRIDES PHARMA INTL WOCKHARDT Viatris AM THERAP Apotex USL PHARMA MORTON GROVE G AND W LABS INC COSETTE CHARTWELL
Active Ingredient: METAPROTERENOL SULFATE

METAPROTERENOL SULFATE Approval History

Loading approval history...

What METAPROTERENOL SULFATE Treats

15 FDA approvals

Originally approved for its first indication in 1987 . Covers 15 distinct patient populations.

  • Other (15)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METAPROTERENOL SULFATE FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA071855 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.